Why I think IMUC is overbought in the short term
The UPenn and Johns Hopkins agreements was news worthy of driving the price up even higher than its current level. They are accumulating the intellectual property rights and setting up to begin testing new candidate in ICT-140 which will expose them to new huge and profitable markets. It also will give ICT-107 additional applications of use.
AMEX listing is positive because many institutional plays will be buying IMUC to fulfill the various biotech funds and sector index requirements.